Smoking cessation through the utilization of pharmacotherapy

Abstract

Smoking cessation is the single most effective behavioral change for disease prevention. While almost 20% of the US population smokes, 70% of these smokers indicate they would like to quit. However, only approximately 3–5% of smokers quit without the aid of some intervention. Best practice suggests that every patient who smokes is offered brief behavioral counseling with pharmacotherapy support for smoking cessation. The past decade has presented new pharmacotherapies for tobacco cessation that allow the clinician more options for individualizing therapy to maximize each patient’s chance for tobacco abstinence. Nicotine replacement therapy, bupropion sustained release and varenicline are discussed as monotherapies and in combination. As the understanding of neuropharmacology increases and new pharmacotherapies are developed, there will be the possibility of tailoring therapies for individual patients based on genetic predispositions and other individual characteristics.

Keywords::

• bupropion
• nicotine replacement
• smoking cessation
• tobacco dependence
• varenicline

Financial and competing interests disclosure

William C Bailey has given lectures sponsored by the following pharmaceutical companies and is on grants as an investigator that may occasionally use a therapy from one of these companies: GlaxoSmithKline, AstraZeneca, Schering-Plough, Merck, Inspire, Rhone Poulenc Rorer, Pfizer, Pharmaceutical Product Dev., Aventis, Boehringer Ingelheim, Altana and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Notes

Adapted from [75].